Kateryna Kostenkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kateryna Kostenkova has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Debbie Catharina Crans
Colorado State University
4 shared publications - Cameron Van Cleave
Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA
3 shared publications - Jordan T. Koehn
Department of Chemistry, Colorado State University, Fort Collins, CO 80523, USA
3 shared publications - Margaret Braasch-Turi
Chemistry Department, Colorado State University, Fort Collins, CO 80523, USA
3 shared publications - Dayane Aparecida Gomes
Universidade Federal de Pernambuco, Brazil
1 shared publication - Eduardo Carvalho Lira
Department of Physiology and Pharmacology, Biosciences Center, UFPE, Av. Professor Moraes Rego - Cidade Universitária, 50670-420. Recife, Pernambuco, Brazil
1 shared publication
Latest Publications
- Open Access
- 30 August 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1232
In Vitro, Oral Acute, and Repeated 28-Day Oral Dose Toxicity of a Mixed-Valence Polyoxovanadate Cluster
Polyoxovanadates (POV) are a subgroup of polyoxometalates (POM), which are nanosized clusters with reported biological activities. This manuscript describes the first toxicity evaluation of a mixed-valence polyoxovanadate, pentadecavanadate, (Me4N)6[V15O36Cl], abbreviated as V15. Cytotoxicity experiments using peripheral blood mononuclear cells (PBMC), larvae of Artemia salina Leach, and in vivo oral acute and repeated 28-day doses in mice was carried out. The LC50 values in PBMC cells and A. salina were 17.5 ± 5.8 μmol L−1, and 17.9 µg L−1, respectively, which indicates high cytotoxic activity. The toxicity in mice was not observed upon acute exposure in a single dose, however, the V15 repeated 28-day oral administration demonstrated high toxicity using 25 mg/kg, 50 mg/kg and, 300 mg/kg doses. The biochemical and hematological analyses during the 28-day administration of V15 showed significant alteration of the metabolic parameters related to the kidney and liver, suggesting moderate toxicity. The V15 toxicity was attributed to the oxidative stress and lipid peroxidation, once thiobarbituric acid (TBAR) levels significantly increased in both males and females treated with high doses of the POV and also in males treated with a lower dose of the POV. This is the first study reporting a treatment-related mortality in animals acutely administrated with a mixed-valence POV, contrasting with the well-known, less toxic decavanadate. These results document the toxicity of this mixed-valence POV, which may not be suitable for biomedical applications.
- 30 August 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (9) , 1232
Open AccessIn Vitro, Oral Acute, and Repeated 28-Day Oral Dose Toxicity of a Mixed-Valence Polyoxovanadate Cluster
Polyoxovanadates (POV) are a subgroup of polyoxometalates (POM), which are nanosized clusters with reported biological activities. This manuscript describes the first toxicity evaluation of a mixed-valence polyoxovanadate, pentadecavanadate, (Me4N)6[V15O36Cl], abbreviated as V15. Cytotoxicity experiments using peripheral blood mononuclear cells (PBMC), larvae of Artemia salina Leach, and in vivo oral acute and repeated 28-day doses in mice was carried out. The LC50 values in PBMC cells and A. salina were 17.5 ± 5.8 μmol L−1, and 17.9 µg L−1, respectively, which indicates high cytotoxic activity. The toxicity in mice was not observed upon acute exposure in a single dose, however, the V15 repeated 28-day oral administration demonstrated high toxicity using 25 mg/kg, 50 mg/kg and, 300 mg/kg doses. The biochemical and hematological analyses during the 28-day administration of V15 showed significant alteration of the metabolic parameters related to the kidney and liver, suggesting moderate toxicity. The V15 toxicity was attributed to the oxidative stress and lipid peroxidation, once thiobarbituric acid (TBAR) levels significantly increased in both males and females treated with high doses of the POV and also in males treated with a lower dose of the POV. This is the first study reporting a treatment-related mortality in animals acutely administrated with a mixed-valence POV, contrasting with the well-known, less toxic decavanadate. These results document the toxicity of this mixed-valence POV, which may not be suitable for biomedical applications.
- 5 May 2022
- Published by Morressier GmbH
Conformation of ubiquinone and menaquinone in model membrane systems
- 5 May 2022
- Published by Morressier GmbH
Conformation of ubiquinone and menaquinone in model membrane systems